Recent Advances in the Treatment and Management of Acute Myeloid Leukemia: Expert Perspectives for Improved Clinical and Economic Outcomes
Publication
, Journal Article
Erba, HP
Published in: Journal of Managed Care Medicine
January 1, 2022
The past decade has witnessed considerable advances in unraveling molecular and genetic underpinnings of acute myeloid leukemia (AML). With a better understanding of the disease, several targeted therapies have been developed which are enhancing survival in AML. Most of these are well-tolerated oral agents.
Duke Scholars
Published In
Journal of Managed Care Medicine
ISSN
1094-1525
Publication Date
January 1, 2022
Volume
25
Issue
1
Start / End Page
56 / 60
Citation
APA
Chicago
ICMJE
MLA
NLM
Erba, H. P. (2022). Recent Advances in the Treatment and Management of Acute Myeloid Leukemia: Expert Perspectives for Improved Clinical and Economic Outcomes. Journal of Managed Care Medicine, 25(1), 56–60.
Erba, H. P. “Recent Advances in the Treatment and Management of Acute Myeloid Leukemia: Expert Perspectives for Improved Clinical and Economic Outcomes.” Journal of Managed Care Medicine 25, no. 1 (January 1, 2022): 56–60.
Erba HP. Recent Advances in the Treatment and Management of Acute Myeloid Leukemia: Expert Perspectives for Improved Clinical and Economic Outcomes. Journal of Managed Care Medicine. 2022 Jan 1;25(1):56–60.
Erba, H. P. “Recent Advances in the Treatment and Management of Acute Myeloid Leukemia: Expert Perspectives for Improved Clinical and Economic Outcomes.” Journal of Managed Care Medicine, vol. 25, no. 1, Jan. 2022, pp. 56–60.
Erba HP. Recent Advances in the Treatment and Management of Acute Myeloid Leukemia: Expert Perspectives for Improved Clinical and Economic Outcomes. Journal of Managed Care Medicine. 2022 Jan 1;25(1):56–60.
Published In
Journal of Managed Care Medicine
ISSN
1094-1525
Publication Date
January 1, 2022
Volume
25
Issue
1
Start / End Page
56 / 60